PANalytical launched new compact benchtop XRF system for pharmaceutical catalysts analysis

PANalytical launched a new Epsilon 1 XRF (X-ray fluorescence) analyzer at last year’s meeting of the American Association of Pharmaceutical Sciences (AAPS), November 2-6, in San Diego, California.

Designed as the most powerful benchtop spectrometer in its class, the new Epsilon 1 provides a compact and cost-effective ‘out-of-the-box’ pre-calibrated solution for the analysis of residual catalysts in pharmaceutical materials.

Metal catalysts are used as part of the pharmaceutical development and manufacturing processes. Post-process efforts are made to remove the undesired catalyst from the material but there are often residues remaining. These residues require comprehensive quantification to meet stringent industry permissible limits, such as those specified in pharmacopoeias including the United States pharmacopoeia and the European pharmacopoeia. The Epsilon 1 will set the new benchmark for analytical performance and ease of use in this class of industry-dedicated XRF instrumentation.

“The need for pharmaceutical catalyst analysis is an industry-wide concern,” commented Pieter de Groot, PANalytical Corporate Marketing Director. “The Epsilon 1 offers a pre-calibrated total solution package, including installation qualification and operation qualification procedures. Designed with simplicity in mind, for the first time PANalytical’s high standards of analysis are now available in this class of desktop instruments.” 

For more information on PANalytical’s innovative range of X-ray based analytical techniques and additive analysis solutions visit the PANalytical website at www.panalytical.com.